News

Otezla is a prescription medicine secured approval to treat patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. The drug is also

“We’re pleased to bring this product to market for the customers and patients who will benefit from access to this medicine and who have in the past experienced

Oral delivery could broaden the clinical and commercial opportunities for RNAi therapeutics, which are currently administered with intravenous or subcutaneous dose administration. The results were presented at the

The EC has approved Talzenna as monotherapy treatment for adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally

The latest FDA approval for Botox is for patients aged between two and 17 years whose movement at the joints of the upper limb is restricted due to

This program will be the first of its kind in the San Francisco Bay Area, which serves as a hub of both tech and biotech industries and is

Treatment with biologic medicines can, in some patients, trigger the body’s immune system to develop anti-drug antibodies. These anti-drug antibodies can reduce the effectiveness of the biologic therapy.

Ultomiris is said to be the first and only long-acting C5 inhibitor administered every eight weeks and it works by inhibiting the C5 protein in the terminal complement

SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of RBM-007. Subjects recruited for the SUSHI Study had wet AMD